Immunotherapy of human leukemia with neuraminidase-modified cells.
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects / Q000276:immunology; D001854:Bone Marrow Cells; D064987:Cell- and Tissue-Based Therapy; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular / Q000187:drug effects; D007115:Immunization Schedule; D007938:Leukemia / Q000276:immunology*; D007939:Leukemia L1210 / Q000276:immunology; D007942:Leukemia, Experimental / Q000276:immunology; D007945:Leukemia, Lymphoid / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000276:immunology; D051379:Mice; D008815:Mice, Inbred Strains; D009439:Neuraminidase / Q000494:pharmacology*; D014734:Vibrio cholerae / Q000201:enzymology
D009439:Neuraminidase